← Back to Search

Unknown

AZD4831 for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by AstraZeneca
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1, day 2 to day 8 and day 14
Awards & highlights

Study Summary

This trial will compare how well and how safe different versions of AZD4831 work in healthy people who have not eaten.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1, day 2 to day 8 and day 14
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1, day 2 to day 8 and day 14 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Area under plasma concentration-time curve from zero to infinity (AUCinf)
Area under the plasma concentration-curve from zero to the last quantifiable concentration (AUClast)
Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t1/2λz)
+6 more
Secondary outcome measures
Number of participants with Adverse Events (AEs)

Trial Design

2Treatment groups
Experimental Treatment
Group I: Sequence 2 (Formulation B + Formulation A)Experimental Treatment1 Intervention
Participants will receive a single oral dose of Treatment 2: Formulation B followed by a washout period of at least 14 days from first dose of AZD4831. After the washout period, participants will receive a single oral dose of Treatment 1 Formulation A.
Group II: Sequence 1 (Formulation A + Formulation B)Experimental Treatment1 Intervention
Participants will receive a single oral dose of Treatment 1: Formulation A followed by a washout period of at least 14 days from first dose of AZD4831. After the washout period, participants will receive a single oral dose of Treatment 2: AZD4831 Formulation B.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AZD4831
2022
Completed Phase 3
~990

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

AstraZenecaLead Sponsor
4,271 Previous Clinical Trials
288,612,829 Total Patients Enrolled
ParexelIndustry Sponsor
304 Previous Clinical Trials
101,158 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Maryland
How old are they?
18 - 65
What site did they apply to?
Research Site
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
A Study to Assess the Relative Bioavailability and Safety of Different Formulations of AZD4831 in Fasted State in Healthy Volunteers.
2022. "A Study to Assess the Relative Bioavailability and Safety of Different Formulations of AZD4831 in Fasted State in Healthy Volunteers.". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05457270.
~11 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top